Withdrawal of low-dose prednisone in sle patients with a clinically quiescent disease for more than 1 year: a randomised controlled trial.
Comment on: “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised controlled trial” by Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hie M, Pineton de Chambron M et al. Annals of the Rheumatic Diseases on-line first Dec 18 2019. Doi 10.1136/annrheumdis-2019-216303. Commented by: Anisur […]
Trial of anifrolumab in active systemic lupus erythematosus.
Comment on: Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2019 Dec 18. doi: 10.1056/NEJMoa1912196. [Epub ahead of print] Commented by: Ricard Cervera, Barcelona, Catalonia, Spain So far, only one biologic targeted therapy, belimumab, has been approved for systemic lupus erythematosus (SLE) and […]